Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (ral-binding protein 1)

Sharad S. Singhal, Jyotsana Singhal, Sushma Yadav, Seema Dwivedi, Paul J. Boor, Yogesh C. Awasthi, Sanjay Awasthi

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Ral-binding protein 1 (RALBP1) is a stress-responsive and stress-protective multispecific transporter of glutathione conjugates (GS-E) and xenobiotic toxins. It is frequently overexpressed in malignant cells and plays a prominent antiapoptotic role selectively in cancer cells through its ability to control cellular concentration of proapoptotic oxidized lipid byproducts. In the absence of chemotherapy, depletion or inhibition of RALBP1 causes regression of syngeneic mouse B16 melanoma. Because RALBP1 transports anthracycline and Vinca alkaloid drugs, as well as GS-E, and because it confers resistance to these drugs, we proposed that depletion or inhibition of RALBP1 should cause regression of human solid tumors that overexpress RALBP1 and augment chemotherapy efficacy. Non-small-cell lung cancer (NSCLC) H358 and H520 and colon SW480 cell lines were used. Cytotoxic synergy between anti-RALBP1 immunoglobulin G (IgG), cis-diammine-dichloroplatinum (II) [CDDP], and vinorelbine was examined in cell culture and xenografts of NSCLC cells. Effects of RALBP1 depletion by antisense were examined in xenografts of NSCLC H358, NSCLC H520, and colon SW480 cells. RALBP1 depletion by phosphorothioate antisense was confirmed and was associated with rapid, complete, and sustained remissions in established s.c. human lung and colon xenografts. RALBP1 inhibition by anti-RALBP1 IgG was equally as effective as antisense and enhanced CDDP-vinorelbine in lung cancer xenografts. These studies show that RALBP1 is a transporter that serves as a key effector function in cancer cell survival and is a valid target for cancer therapy, and confirm that inhibitory modulation of RALBP1 transport activity at the cell surface is sufficient for antitumor effects.

Original languageEnglish (US)
Pages (from-to)4382-4389
Number of pages8
JournalCancer Research
Volume67
Issue number9
DOIs
StatePublished - May 1 2007

Fingerprint

ral GTP-Binding Proteins
Heterografts
Colonic Neoplasms
Lung Neoplasms
Carrier Proteins
Non-Small Cell Lung Carcinoma
Immunoglobulin G
Protein Transport
Neoplasms
Colon
Vinca Alkaloids
Drug Therapy
Experimental Melanomas
Anthracyclines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Singhal, S. S., Singhal, J., Yadav, S., Dwivedi, S., Boor, P. J., Awasthi, Y. C., & Awasthi, S. (2007). Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (ral-binding protein 1). Cancer Research, 67(9), 4382-4389. https://doi.org/10.1158/0008-5472.CAN-06-4124

Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (ral-binding protein 1). / Singhal, Sharad S.; Singhal, Jyotsana; Yadav, Sushma; Dwivedi, Seema; Boor, Paul J.; Awasthi, Yogesh C.; Awasthi, Sanjay.

In: Cancer Research, Vol. 67, No. 9, 01.05.2007, p. 4382-4389.

Research output: Contribution to journalArticle

Singhal, SS, Singhal, J, Yadav, S, Dwivedi, S, Boor, PJ, Awasthi, YC & Awasthi, S 2007, 'Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (ral-binding protein 1)', Cancer Research, vol. 67, no. 9, pp. 4382-4389. https://doi.org/10.1158/0008-5472.CAN-06-4124
Singhal, Sharad S. ; Singhal, Jyotsana ; Yadav, Sushma ; Dwivedi, Seema ; Boor, Paul J. ; Awasthi, Yogesh C. ; Awasthi, Sanjay. / Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (ral-binding protein 1). In: Cancer Research. 2007 ; Vol. 67, No. 9. pp. 4382-4389.
@article{793f571591fb46d39b3b280d05ffbeaa,
title = "Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (ral-binding protein 1)",
abstract = "Ral-binding protein 1 (RALBP1) is a stress-responsive and stress-protective multispecific transporter of glutathione conjugates (GS-E) and xenobiotic toxins. It is frequently overexpressed in malignant cells and plays a prominent antiapoptotic role selectively in cancer cells through its ability to control cellular concentration of proapoptotic oxidized lipid byproducts. In the absence of chemotherapy, depletion or inhibition of RALBP1 causes regression of syngeneic mouse B16 melanoma. Because RALBP1 transports anthracycline and Vinca alkaloid drugs, as well as GS-E, and because it confers resistance to these drugs, we proposed that depletion or inhibition of RALBP1 should cause regression of human solid tumors that overexpress RALBP1 and augment chemotherapy efficacy. Non-small-cell lung cancer (NSCLC) H358 and H520 and colon SW480 cell lines were used. Cytotoxic synergy between anti-RALBP1 immunoglobulin G (IgG), cis-diammine-dichloroplatinum (II) [CDDP], and vinorelbine was examined in cell culture and xenografts of NSCLC cells. Effects of RALBP1 depletion by antisense were examined in xenografts of NSCLC H358, NSCLC H520, and colon SW480 cells. RALBP1 depletion by phosphorothioate antisense was confirmed and was associated with rapid, complete, and sustained remissions in established s.c. human lung and colon xenografts. RALBP1 inhibition by anti-RALBP1 IgG was equally as effective as antisense and enhanced CDDP-vinorelbine in lung cancer xenografts. These studies show that RALBP1 is a transporter that serves as a key effector function in cancer cell survival and is a valid target for cancer therapy, and confirm that inhibitory modulation of RALBP1 transport activity at the cell surface is sufficient for antitumor effects.",
author = "Singhal, {Sharad S.} and Jyotsana Singhal and Sushma Yadav and Seema Dwivedi and Boor, {Paul J.} and Awasthi, {Yogesh C.} and Sanjay Awasthi",
year = "2007",
month = "5",
day = "1",
doi = "10.1158/0008-5472.CAN-06-4124",
language = "English (US)",
volume = "67",
pages = "4382--4389",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (ral-binding protein 1)

AU - Singhal, Sharad S.

AU - Singhal, Jyotsana

AU - Yadav, Sushma

AU - Dwivedi, Seema

AU - Boor, Paul J.

AU - Awasthi, Yogesh C.

AU - Awasthi, Sanjay

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Ral-binding protein 1 (RALBP1) is a stress-responsive and stress-protective multispecific transporter of glutathione conjugates (GS-E) and xenobiotic toxins. It is frequently overexpressed in malignant cells and plays a prominent antiapoptotic role selectively in cancer cells through its ability to control cellular concentration of proapoptotic oxidized lipid byproducts. In the absence of chemotherapy, depletion or inhibition of RALBP1 causes regression of syngeneic mouse B16 melanoma. Because RALBP1 transports anthracycline and Vinca alkaloid drugs, as well as GS-E, and because it confers resistance to these drugs, we proposed that depletion or inhibition of RALBP1 should cause regression of human solid tumors that overexpress RALBP1 and augment chemotherapy efficacy. Non-small-cell lung cancer (NSCLC) H358 and H520 and colon SW480 cell lines were used. Cytotoxic synergy between anti-RALBP1 immunoglobulin G (IgG), cis-diammine-dichloroplatinum (II) [CDDP], and vinorelbine was examined in cell culture and xenografts of NSCLC cells. Effects of RALBP1 depletion by antisense were examined in xenografts of NSCLC H358, NSCLC H520, and colon SW480 cells. RALBP1 depletion by phosphorothioate antisense was confirmed and was associated with rapid, complete, and sustained remissions in established s.c. human lung and colon xenografts. RALBP1 inhibition by anti-RALBP1 IgG was equally as effective as antisense and enhanced CDDP-vinorelbine in lung cancer xenografts. These studies show that RALBP1 is a transporter that serves as a key effector function in cancer cell survival and is a valid target for cancer therapy, and confirm that inhibitory modulation of RALBP1 transport activity at the cell surface is sufficient for antitumor effects.

AB - Ral-binding protein 1 (RALBP1) is a stress-responsive and stress-protective multispecific transporter of glutathione conjugates (GS-E) and xenobiotic toxins. It is frequently overexpressed in malignant cells and plays a prominent antiapoptotic role selectively in cancer cells through its ability to control cellular concentration of proapoptotic oxidized lipid byproducts. In the absence of chemotherapy, depletion or inhibition of RALBP1 causes regression of syngeneic mouse B16 melanoma. Because RALBP1 transports anthracycline and Vinca alkaloid drugs, as well as GS-E, and because it confers resistance to these drugs, we proposed that depletion or inhibition of RALBP1 should cause regression of human solid tumors that overexpress RALBP1 and augment chemotherapy efficacy. Non-small-cell lung cancer (NSCLC) H358 and H520 and colon SW480 cell lines were used. Cytotoxic synergy between anti-RALBP1 immunoglobulin G (IgG), cis-diammine-dichloroplatinum (II) [CDDP], and vinorelbine was examined in cell culture and xenografts of NSCLC cells. Effects of RALBP1 depletion by antisense were examined in xenografts of NSCLC H358, NSCLC H520, and colon SW480 cells. RALBP1 depletion by phosphorothioate antisense was confirmed and was associated with rapid, complete, and sustained remissions in established s.c. human lung and colon xenografts. RALBP1 inhibition by anti-RALBP1 IgG was equally as effective as antisense and enhanced CDDP-vinorelbine in lung cancer xenografts. These studies show that RALBP1 is a transporter that serves as a key effector function in cancer cell survival and is a valid target for cancer therapy, and confirm that inhibitory modulation of RALBP1 transport activity at the cell surface is sufficient for antitumor effects.

UR - http://www.scopus.com/inward/record.url?scp=34249322665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249322665&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-06-4124

DO - 10.1158/0008-5472.CAN-06-4124

M3 - Article

VL - 67

SP - 4382

EP - 4389

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 9

ER -